Stay updated on Savolitinib Combo in EGFRm+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the savolitinib study is displayed, including its study design, eligibility criteria, outcomes, locations, and data-sharing information.
    Difference
    65%
    Check dated 2026-11-08T14:12:14.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0 while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:41:29.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A banner announces an NIH website transition and says the term “Super Intelligence” may appear in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T18:53:57.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T22:31:38.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1. The page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T22:32:30.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the prior study content with a standard error screen. This prevents viewing the study details from the ClinicalTrials.gov entry.
    Difference
    19%
    Check dated 2026-09-20T20:35:31.000Z thumbnail image

Stay in the know with updates to Savolitinib Combo in EGFRm+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page.